In this study, we sought to compare the concordance of pathogenic alterations in PIK3CA, AKT1, AKT2, AKT3, and PTEN detected by tissue-based FoundationOne®CDx and blood-based FoundationOne®Liquid CDx in contemporaneous samples collected from patients with breast cancer. This evidence concerns the gene AKT3 and breast cancer.